Anti-GAD Encephalitis Following COVID-19 Vaccination: A Case Report
dc.authorid | ALTUNAN, BENGU/0000-0001-6034-8808 | |
dc.contributor.author | Deniz, Cigdem | |
dc.contributor.author | Altunan, Bengu | |
dc.contributor.author | Unal, Aysun | |
dc.date.accessioned | 2024-10-29T17:59:07Z | |
dc.date.available | 2024-10-29T17:59:07Z | |
dc.date.issued | 2023 | |
dc.department | Tekirdağ Namık Kemal Üniversitesi | |
dc.description.abstract | Since December 2020, a significantly higher number of people worldwide have been vaccinated for coronavirus disease 2019 (COVID-19). Neurological complications have been reported after these vaccines, although a definitive causal relationship has not been proven in the available literature. We describe a 51-year-old man presenting with anti-glutamic acid decarboxylase (anti-GAD) antibody positive autoimmune encephalitis with progressive cognitive impairment and behavioral abnormalities, presenting shortly after the second dose of mRNA COVID-19 vaccine, possibly representing a serious vaccine related adverse event. Response to high-dose steroid and intravenous immunoglobulin treatment was positive. As many people around the world have been vaccinated against COVID-19, this case shows that autoimmune encephalitis and even anti-GAD antibody positive autoimmune encephalitis can develop as a side effect after this new vaccine, but with early diagnosis and appropriate treatment, the clinic can have a good prognosis. Observational studies with large numbers of patients are needed to explain causality. | |
dc.identifier.doi | 10.29399/npa.28251 | |
dc.identifier.endpage | 287 | |
dc.identifier.issn | 1300-0667 | |
dc.identifier.issn | 1309-4866 | |
dc.identifier.issue | 3 | en_US |
dc.identifier.pmid | 37645084 | |
dc.identifier.scopus | 2-s2.0-85168563981 | |
dc.identifier.scopusquality | Q3 | |
dc.identifier.startpage | 283 | |
dc.identifier.trdizinid | 1228589 | |
dc.identifier.uri | https://doi.org/10.29399/npa.28251 | |
dc.identifier.uri | https://search.trdizin.gov.tr/tr/yayin/detay/1228589 | |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/14630 | |
dc.identifier.volume | 60 | |
dc.identifier.wos | WOS:001055620100014 | |
dc.identifier.wosquality | Q4 | |
dc.indekslendigikaynak | Web of Science | |
dc.indekslendigikaynak | Scopus | |
dc.indekslendigikaynak | TR-Dizin | |
dc.indekslendigikaynak | PubMed | |
dc.language.iso | en | |
dc.publisher | Turkish Neuropsychiatry Assoc-Turk Noropsikiyatri Dernegi | |
dc.relation.ispartof | Noropsikiyatri Arsivi-Archives of Neuropsychiatry | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | anti-GAD encephalitis | |
dc.subject | autoimmune encephalitis | |
dc.subject | COVID-19 vaccination | |
dc.title | Anti-GAD Encephalitis Following COVID-19 Vaccination: A Case Report | |
dc.title.alternative | COVID-19 Aşısını Takiben Gelişen Anti-GAD Ensefalit: Olgu Sunumu | |
dc.type | Article |